Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese communi...

Post time 1 hour(s) ago

Suga, T., Oiwa, H., Ishida, M. et al. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital. Clin Rheumatol 41, 2803–2808 (2022). https://doi.org/10.1007/s10067-022-06166-3

Received20 January 2022
Revised18 February 2022
Accepted03 April 2022
Published11 April 2022
Version of record11 April 2022
Issue dateSeptember 2022
DOIhttps://doi.org/10.1007/s10067-022-06166-3

Keywords

Post time Half hour(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese communi...

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese communi... Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese communi...